Aimmune Agrees to be Acquired by Nestl? Health Science
- Soci?t?s des Produits Nestl? S.A., part of Nestl? Health Science, to acquire Aimmune for?$34.50?per share in cash, representing a total equity value of?$2.6 Billion?and a 174% premium to Aimmune?s closing price on?August 28, 2020
- Aimmune?s PALFORZIA??[Peanut (Arachis hypogaea) Allergen Powder-dnfp] is the world?s first approved treatment for peanut allergy
- Transaction expected to be completed in the fourth quarter of 2020
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20200830005025/en/
Investors: DeDe Sheel (917) 834-1494 dsheel@aimmune.com Media: Jodi Sievers (650) 823-3253 jsievers@aimmune.com Julie Normart (559) 974-3245 jnormart@w2ogroup.com Source:?Aimmune Therapeutics Inc.